CN203144402U - Kit for antineoplastic drug sensitivity test - Google Patents
Kit for antineoplastic drug sensitivity test Download PDFInfo
- Publication number
- CN203144402U CN203144402U CN 201320159646 CN201320159646U CN203144402U CN 203144402 U CN203144402 U CN 203144402U CN 201320159646 CN201320159646 CN 201320159646 CN 201320159646 U CN201320159646 U CN 201320159646U CN 203144402 U CN203144402 U CN 203144402U
- Authority
- CN
- China
- Prior art keywords
- drug
- culture plate
- medicine
- film
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The utility model provides a kit for antineoplastic drug sensitivity test. The kit is composed of a kit body, a drug sensitivity test assembly, a designation card and an instruction book, wherein the drug sensitivity test assembly, the designation card and the instruction book are arranged in the kit body. The kit is characterized in that the drug sensitivity test assembly comprises an antineoplastic drug membrane, a blank drug membrane and a cell culture plate, the antineoplastic drug membrane, the blank drug membrane and the cell culture plate in the drug sensitivity test assembly are pre-installed according to a preset chemotherapy regimen to form a pre-installed culture plate, or the antineoplastic drug membrane and the blank drug membrane are individually packaged and form adjustable assorted culture plates together with the cell culture plate. In an antineoplastic drug sensitivity test, the kit provided by the utility model not only improves the operation efficiency of the antineoplastic drug sensitivity test and ensures simple and convenient operation, but also guarantees accurate and adjustable dosage, greatly improves the drug sensitivity test accuracy, greatly reduces the dosage of test drug, lowers the drug cost and improves the economical efficiency of the drug sensitivity test, and the kit is particularly suitable for drug sensitivity test of combined chemotherapy.
Description
Technical field
The utility model relates to a kind of device of antitumor susceptibility test, specifically, relates to a kind of test kit for antitumor susceptibility detection.
Background technology
Malignant tumour is serious harm human life and healthy common disease and frequently-occurring disease, is to cause one of disabled and early dead principal disease, and in 35～59 years old age group, malignant tumour occupies first of the cause of the death.Data shows that sending out case load China's malignant tumour year is 2,000,000, and is dead about 1,500,000, and with 3% speed increase and be rejuvenation trend, occupy mortality ratio in all kinds of diseases.
The world comprises operation, radiotherapy, chemotherapy, endocrine therapy and biological immune treatment etc. to the main treatment means of malignant tumour at present.In many means for the treatment of malignant tumor, chemotherapy is as a kind of methods for the treatment of of general, might farthest kill tumour cell in patient's body than additive method, and therefore, chemotherapy is occupied important status in treating malignant tumor.Along with the development of medical science, chemotherapy no longer has been the means that play the palliative therapy effect merely, from appeasing to the radical cure transition.
1998, the World Health Organization proposes, use suitably, chemotherapy has become the radical treatment means that can cure tumour in part tumour (malignant trophoblastic tumor, acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, carcinoma of testis, acute myeloblastic leukemia, embryonal rhabdomyosarcoma, skin carcinoma, small cell lung cancer and ovarian cancer etc.).After adjuvant chemotherapy, can mammary cancer, osteogenic sarcoma, large bowel cancer, osteosarcoma, retinoblastoma, soft tissue sarcoma and the nephroblastoma etc. be arranged curable tumour.
Antitumor is that a kind of grade malignancy compares tumors of higher.Multiplely be born in the elderly, developed country's sickness rate is higher than developing country.Along with the change of China's growth in the living standard and dietary structure, antineoplastic sickness rate presents the trend of rising in recent years, and the tendency of rejuvenation is arranged.
Chemotherapeutical purpose be prolong lifetime, the quality of making the life better and improve the effect of other treatments such as operation, comprise postoperative adjuvant chemotherapy and at the chemotherapy of appeasing of not accepting the radical treatment patient.In recent years, at some big pancreas centers, be that the new adjuvant chemotherapy of purpose also has more application to improve surgical result or to improve the excision rate before the art.
Although chemotherapy is occupied important status in the treatment of malignant tumour, in clinical practice, the result is often not fully up to expectations.Wherein, it is the common factor that causes the chemotherapy of tumors failure that tumour cell produces resistance to chemotherapeutics, also is the key difficult problem of puzzlement oncotherapy.The resistance problem is very general clinical problem, estimates according to American Cancer Society, and the patient because of tumor mortality more than 90% is being subjected to the resistance influence in varying degrees.
Drug resistance of tumor cell is divided into primary and acquired resistance two big classes.Common way is clinically at present, follow the card result of study according to the test of international clinical tumor, learn that different chemotherapeutics is to different tumor treatment susceptibility differences, be that each tumour has corresponding effective chemotherapy medicament sensitive spectrum, thereby the scheme for combining of selecting the single medicine of the highest chemotherapy of curative effect or multiple medicine to form is treated.But often run into such situation clinically, be known as the effective treatment plan of certain tumour through following card research, and the patient who has is had no effect.Be a kind of medicine with milestone significance as Zorubicin to infiltrative breast carcinoma, but still have 50% infiltrative breast carcinoma patient insensitive to this medicine.And for example strong selecting is obvious to antitumor generally acknowledged curative effect, but also has the patient's curative effect more than 60% also not obvious.
Tumour exists tangible individual difference to various chemotherapeutics.Be different tumor types or the different patients of same type, even same patient is in the different morbidity stages, to the susceptibility of chemotherapy and incomplete same, the result for the treatment of difference is also very big.So far the combined utilization that does not also have a kind of chemotherapeutics or several chemotherapeutics can be effective to a certain tumour 100%.Clinically, use with a kind of chemotherapeutics or with the different tumour patient of a kind of chemotherapy regimen treatment, obviously have certain blindness.Therefore, carrying out the tumour drug sensitive test at different patients before chemotherapy selects effective chemotherapeutics to carry out chemotherapy to seem very necessary.For this reason, set up a kind ofly as the bacterium sensitization test, by sensitivity testing method relatively reliably, different patients is accurately screened responsive chemotherapeutics, and determine its dosage, really realize clinical personalized medicine.
Tumour drug sensitive test is at present operated required medicine to face with now joining, and the tumour drug sensitive test need be tested multiple antitumor drug, and the soup prepared and diluted is loaded down with trivial details, and the required antitumor drug dosage of tumour drug sensitive test is little, sampling inconvenience.The part drug solution following shelf time of state is short, and remainder can only be scrapped, and causes the waste of medicine, especially expensive medicine.
CN93111551.5 discloses tumour chemotherapy medicament sensitive pretest agent compounding method and test kit, and this patent is pre-installed on 8 kinds of antitumor drugs commonly used in the specimen bottle by setting dosage.But this method is not easy to the test of Combination chemotherapy, and is not easy to the dose titration of scheme.
CN03102260.X adopts the method for prefabricated medicine sensitive detecting plate, and antitumor drug is added in the check-out console by calculating dosage, and freeze-drying, packing are used for the tumour drug sensitive test.This method is not easy to the test of Combination chemotherapy equally, and is not easy to the dose titration of scheme.
Clinical have the method for the interim preparation of a small amount of employing antitumor drug to carry out the antitumor drug antibiotics susceptibility test at present, and still, there are many problems in this method: accurate concentration the unknown of compounding pharmaceutical, and the accuracy of institute's preparating liquid leaves a question open; The antitumor drug antibiotics susceptibility test of clinical oral administration antitumor drug can't carry out; The individual operations error is big.
For the ease of the operation of tumour drug sensitive test and save cost, we will various anti-tumor tumour medicines commonly used be prepared into, and dosage is accurate, good stability, can be in tumor cell culture liquid rapidly-soluble aseptic medicine film.And the medicine film cut into slices packing accurately by using dosage.
The utility model content
The utility model relates to a kind of device of antitumor susceptibility test, specifically, relates to a kind of test kit for antitumor susceptibility test.
Technical solutions of the utility model are as follows:
The test kit that a kind of antitumor susceptibility detects, formed by box body, antibiotics susceptibility test assembly, designation card and specification sheets, antibiotics susceptibility test assembly, designation card and specification sheets place in the box, it is characterized in that described antibiotics susceptibility test assembly comprises antitumor drug medicine film, blank medicine film and Tissue Culture Plate.
Test kit described above is characterized in that described antibiotics susceptibility test assembly also comprises medicine activating enzymes packing.
Test kit described above is characterized in that in the described antibiotics susceptibility test assembly, and antitumor drug medicine film and blank medicine film and Tissue Culture Plate form the prepackage culture plate by setting the chemotherapy regimen prepackage.
Test kit described above is characterized in that in the described antibiotics susceptibility test assembly that antitumor drug medicine film and blank medicine film have been formed adjustable suit culture plate with independent packaging and Tissue Culture Plate respectively.
Test kit described above is characterized in that described antitumor drug medicine film is selected from prevention or treats in the medicine medicine film of following tumour a kind of or two or more: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, hairy cell, cholangiocarcinoma, multiple myeloma, malignant melanoma, malignant mesothelioma, nonsmall-cell lung cancer, small cell lung cancer, liver cancer, cancer of anal canal, carcinoma of testis, thyroid carcinoma, colorectal cancer, tumor colli, Kaposi sarcoma, carcinoid, Hodgkin lymphoma, non-Hodgkin lymphoma, be primary in the lymphoma of cental system, the epithelial origin ovarian cancer, sexual cell source ovarian cancer, cerebral tumor, bladder cancer, prostate cancer, mammary cancer, soft tissue sarcoma, renal cell carcinoma, the esophageal carcinoma, tumor of head and neck, cancer of the stomach, the stomach and intestine mesenchymal neoplasm, thymoma, carcinoma of the pancreas or carcinoma of endometrium.
Test kit described above is characterized in that described Tissue Culture Plate is 24 porocyte culture plates.
Test kit described above, wherein said medicine activating enzymes are selected from P450 enzyme system, Procaine esterase, cytidine deaminase, thymidine phosphorylase, phosphamidase, the Phosphoric acid esterase a kind of or two or more.
The utility model is a kind of test kit for anti-tumor tumour antibiotics susceptibility test, and susceptibility test suite packaged form is by the prepackage culture plate of setting the chemotherapy regimen prepackage and two kinds of the adjustable suits that make up of medicine film packing and blank 24 porocyte culture plates independently with antitumor drug medicine film and 24 porocyte culture plates in the test kit.
Contain antitumor antitumor drug medicine film packing box, a Tissue Culture Plate commonly used in each adjustable suit.The code name of each medicine film is arranged on the medicine film packing, and each Tissue Culture Plate attaches a designation card, is used for pharmaceutical cpd in each hole of mark.
Various antitumour drug films and blank medicine film place independently aseptic the lid in the small plastic box respectively, in the big plastics casing of again small plastic box being packed in order.Various medicine activating enzymes place independently aseptic the lid in the small plastic box respectively, in the big plastics casing of again small plastic box being packed in order.
Tissue Culture Plate is 24 porocyte culture plates, and designation card is 24 lattice, is used for the pharmaceutical cpd in each hole of mark.
During use, blank, the contrast of blank medicine film and various chemotherapy regimen are marked on respectively on the designation card, press the designation card content and add the medicine film in Tissue Culture Plate, add the tumour cell suspension, vibration makes medicine film dissolving mixing.
The chemotherapy regimen that the prepackage culture plate sets is worked out with reference to the standard chemotherapy regimen of up-to-date practice guidelines.By the setting scheme medicine film is packed in each hole of culture plate.
Medicine medicine film described in the utility model, normally, medicine medicine film contains 0.0001%～30% antitumor drug, 50%～98% film forming material and 1%～20% softening agent by weight percentage.Wherein, described film forming material includes but not limited to polyvinyl alcohol, hypromellose, hydroxypropylcellulose, Xylo-Mucine, polyvinylpyrrolidone, polyethylene amine, polyethylene amido-acetal derivative, polyvinyl pyridine derivative, gelatin, gum arabic, shellac, agar, Lalgine and salt thereof, zein, starch, dextrin, bletilla striata glue etc.Preferred polyvinyl alcohol 04-88 and the polyvinyl alcohol 05-88 of using.Described softening agent is selected from glycerine, polyoxyethylene glycol, ethylene glycol, propylene glycol, sorbyl alcohol, triethyl citrate etc.
Medicine medicine film described in the utility model can prepare with ordinary method in this area, for example can make antitumor drug medicine film as follows:
(1) film forming material is added to the water stirring and dissolving or heating for dissolving;
(2) add softening agent and antitumor drug, stirring and dissolving is even, adopts heating, leaves standstill or mode such as ultrasonic outgases;
(3) with above-mentioned solution coat in membrane equipment, adopt mode dryings such as hot blast or cold wind;
(4) demoulding is measured content, and carries out divided dose according to measurement result and cut apart;
(5) the medicine film after will cutting apart adopts radiation exposure sterilization or ethylene oxide sterilizing, preferred radiation exposure sterilization.
The plasma peak concentration preparation of various tumor chemotherapeutic drug medicine film reference drugs in human body according to medicine film assay result, is cut into the chemotherapeutics that contains the 1ml plasma peak concentration with every medicine film, blank medicine film cutting area 1cm
2
For the ease of the operation of tumour antibiotics susceptibility test, the medicine film needs and can be dissolved in fast in the tumor cell culture liquid.Therefore film forming material will be easy to dissolving, and the thickness of film and area will be controlled in suitable scope, guarantees dissolution rate and physical strength.Preferred 0.04mm～the 0.15mm of thickness.Shape can be circle, square or rectangular, and area is preferably 0.5cm
2～16cm
2, to adapt to the Tissue Culture Plate of corresponding specification.1cm of the present invention
2The film of size can dissolving in 100 seconds in the 1ml nutrient solution.
Described blank medicine film refers to not contain the medicine film of antitumor drug, can be prepared according to above-mentioned antitumor drug medicine membrane method, but not add antitumor drug.
The utility model is in carrying out antitumor susceptibility test, not only improve the operation efficiency of tumour antibiotics susceptibility test, make easy and simple to handle, and improved the accuracy of antibiotics susceptibility test greatly, significantly reduce the testing drug consumption, save drug cost, improve the economy of antibiotics susceptibility test, particularly, also be applicable to the antibiotics susceptibility test of combined chemotherapy.
Description of drawings
24 well culture plate vertical views of adjustable suit culture plate in Fig. 1: embodiment 1 utility model;
24 well culture plate plan views of adjustable suit culture plate in Fig. 2: embodiment 1 utility model;
Designation card in Fig. 3: embodiment 1 utility model.
Wherein:
Among Fig. 1,2, A-D is the hole row number of culture plate, and 1-6 is the hole row number of culture plate, and the combination of the row of hole correspondence number and row number is the numbering in hole, and for example: A6 represents in the hole hole of capable the 6th row of the A of culture plate.
Among Fig. 3, every lattice numbering in the designation card is corresponding to the hole numbering of culture plate.
Embodiment
Below be example to be used for acute lymphoblastic leukemia susceptibility detection kit, the utility model is described.But it does not constitute restriction of the present utility model.
Embodiment 1: the susceptibility detection kit that is used for the screening anti-tumor medicine of acute lymphoblastic leukemia
The utility model test kit is made up of box body, susceptibility detection components, designation card (Fig. 3) and specification sheets, and susceptibility detection components, designation card (Fig. 3) and specification sheets place in the box.The susceptibility detection components is that anti-acute leukemia medicine medicine film and blank medicine film have been formed adjustable suit culture plate with independent packaging and Tissue Culture Plate (Fig. 1 or 2) respectively, be that the susceptibility detection components is made up of 24 well culture plates (shown in Fig. 1 or 2) and big plastics casing, have the antitumor drug medicine film that is used for acute lymphoblastic leukemia of independent packaging, the blank medicine film of independent packaging, the medicine activating enzymes (hepatomicrosome) of independent packaging to form in the big plastics casing.Various antitumour drug films and blank medicine film place independently aseptic the lid in the small plastic box respectively, in the big plastics casing of again small plastic box being packed in order; The medicine activating enzymes place independently aseptic the lid in the small plastic box, in the big plastics casing of again small plastic box being packed in order.
Susceptibility detection components, designation card and specification sheets place box, become the susceptibility detection kit for the screening anti-tumor medicine of acute lymphoblastic leukemia.Specification sheets is explanation and introduces test kit, is convenient to the user and correctly uses this test kit.
Before chemotherapy, extract 20 routine acute lymphoblastic leukemia peripheral blood of patients 10ml (anticoagulant heparin) under the Aseptic technique, in the decontamination chamber, isolate the leukemia cell through FIcoll liquid, through the nutrient solution washing, place the RPMI1640 culture system to make 1 * 10
6The cell suspension of/ml.
The cell suspension kind is established cell control group (tumour cell suspension), blank medicine film control group (tumour cell suspension+blank medicine film), experimental group (tumour cell suspension+chemotherapeutic film) in 24 well culture plates (Fig. 1 or 2) (1ml/ hole).Add corresponding medicine film and activating enzymes to each hole of culture plate, and be recorded on the designation card (Fig. 3).Add cell suspension 1ml/ hole to each hole, vibration makes medicine film dissolving mixing.37 ℃, 5% carbonic acid gas saturated humidity were cultivated 24 hours.Centrifugal collection suspension cell, Eppendorf centrifuge rotating speed 2000RPM, centrifugation time 5min abandons substratum.With twice of cold PBS washed cell (2000RPM, centrifugation time 5min collecting cell).With 400 μ l 1X Binding Buffer suspension cells, concentration is approximately 1 * 10
6/ ml.In cell suspending liquid, add 5 μ l Annexin V-FITC, under 2-8 ℃ of lucifuge condition, hatched 15 minutes behind the mixing gently.Adding behind the 10ul PI gently mixing hatched 5 minutes under 2-8 ℃ of lucifuge condition.In 1 hour, detect control group and medicine group apoptosis and downright bad quantity with flow cytometer, calculate the inhibiting rate of medicine, the susceptibility of assessment medicine.
It is as follows to add each hole Chinese medicine film:
A1-A2 blank (cell control group, no medicine film)
The blank medicine film of A3-A4 (the blank medicine film that does not contain medicine is as blank medicine film contrast)
A5 vincristine(VCR) film
A6 Etoposide film
B1 methotrexate film
B2 cytosine arabinoside film
B3 hydroxycamptothecine film
B4 homoharringtonine film
B5 daunorubicin film
B6 mitoxantrone film
C1 Zorubicin film
C2 Carubicin film
C3 vindesine film
C4 epirubicin film
C5 aclarubicin film
C6 pirarubicin film
D1 teniposide film
D2 endoxan film and hepatomicrosome
D3 mitoxantrone film and cytosine arabinoside film
D4 teniposide film and cytosine arabinoside film
D5 daunorubicin film, vincristine(VCR) film, endoxan film and hepatomicrosome
D6 daunorubicin film, vincristine(VCR) film and dexamethasone film.
Acute lymphoblastic leukemia susceptibility detected result is as shown in table 1 below.
The susceptibility of table 1 antibiotics susceptibility test
(inhibiting rate=((blank medicine film control group viable cell-experimental group viable cell)/blank medicine film control group viable cell) * 100%; Inhibiting rate＞50% is responsive).
Claims (7)
1. one kind is used for the test kit that antitumor susceptibility detects, formed by box body, antibiotics susceptibility test assembly, designation card and specification sheets, antibiotics susceptibility test assembly, designation card and specification sheets place in the box, it is characterized in that described antibiotics susceptibility test assembly comprises antitumor drug medicine film, blank medicine film and Tissue Culture Plate.
2. test kit according to claim 1, if desired, described antibiotics susceptibility test assembly also can comprise medicine activating enzymes packing.
3. test kit according to claim 1 is characterized in that in the described antibiotics susceptibility test assembly, and antitumor drug medicine film and blank medicine film and Tissue Culture Plate form the prepackage culture plate by setting the chemotherapy regimen prepackage.
4. test kit according to claim 1 is characterized in that in the described antibiotics susceptibility test assembly, and antitumor drug medicine film and blank medicine film have been formed adjustable suit culture plate with independent packaging and Tissue Culture Plate respectively.
5. according to each described test kit of claim 1-4, it is characterized in that described antitumor drug medicine film is selected from prevention or treats in the medicine medicine film of following tumour a kind of or two or more: acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, hairy cell, cholangiocarcinoma, multiple myeloma, malignant melanoma, malignant mesothelioma, nonsmall-cell lung cancer, small cell lung cancer, liver cancer, cancer of anal canal, carcinoma of testis, thyroid carcinoma, colorectal cancer, tumor colli, Kaposi sarcoma, carcinoid, Hodgkin lymphoma, non-Hodgkin lymphoma, be primary in the lymphoma of cental system, the epithelial origin ovarian cancer, sexual cell source ovarian cancer, cerebral tumor, bladder cancer, prostate cancer, mammary cancer, soft tissue sarcoma, renal cell carcinoma, the esophageal carcinoma, tumor of head and neck, cancer of the stomach, the stomach and intestine mesenchymal neoplasm, thymoma, carcinoma of the pancreas or carcinoma of endometrium.
6. test kit according to claim 2, it is a kind of or two or more to it is characterized in that described medicine activating enzymes are selected from P450 enzyme system, Procaine esterase, cytidine deaminase, thymidine phosphorylase, phosphamidase, the Phosphoric acid esterase.
7. according to each described test kit of claim 1-4, it is characterized in that described Tissue Culture Plate is 24 porocyte culture plates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320159646 CN203144402U (en) | 2013-03-26 | 2013-03-26 | Kit for antineoplastic drug sensitivity test |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201320159646 CN203144402U (en) | 2013-03-26 | 2013-03-26 | Kit for antineoplastic drug sensitivity test |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203144402U true CN203144402U (en) | 2013-08-21 |
Family
ID=48971945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201320159646 Expired - Fee Related CN203144402U (en) | 2013-03-26 | 2013-03-26 | Kit for antineoplastic drug sensitivity test |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203144402U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106248922A (en) * | 2016-07-22 | 2016-12-21 | 嘉兴鼎诺生物科技有限公司 | A kind of drug sensitive test of tumor cell detection plate and detection method |
-
2013
- 2013-03-26 CN CN 201320159646 patent/CN203144402U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106248922A (en) * | 2016-07-22 | 2016-12-21 | 嘉兴鼎诺生物科技有限公司 | A kind of drug sensitive test of tumor cell detection plate and detection method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ling et al. | Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway | |
| Shang et al. | Experimental study of anti-tumor effects of polysaccharides from Angelica sinensis | |
| Elhag et al. | The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines | |
| Wu et al. | Pyroptosis, a new breakthrough in cancer treatment | |
| CN109864991B (en) | Application of cryptotanshinone in preparation of Ph + acute lymphocytic leukemia chemotherapy sensitization drug | |
| CN203144402U (en) | Kit for antineoplastic drug sensitivity test | |
| CN107898804A (en) | A kind of application of anti-tumor agent comprising salmosin in human leukemia cell | |
| Juan et al. | Probiotics for the treatment of docetaxel-related weight gain of breast cancer patients—a single-center, randomized, double-blind, and placebo-controlled trial | |
| CN203144399U (en) | Kit for colorectal cancer susceptibility detection | |
| Liu et al. | Ganoderma lucidum fruiting body extracts inhibit colorectal cancer by inducing apoptosis, autophagy, and G0/G1 phase cell cycle arrest in vitro and in vivo | |
| CN203144410U (en) | Kit for breast cancer drug sensitivity test | |
| CN203144400U (en) | Kit for acute leukemia susceptibility detection | |
| CN103088102A (en) | Sterile instant type medicine film and tumor drug sensitivity testing application thereof | |
| KR102024322B1 (en) | A composition for enhancing radiation sensitivity and an anticancer adjuvent composition comprising ginsenoside rg3 | |
| CN203144403U (en) | Kit for detecting drug sensitivity of pancreatic cancer | |
| CN203144408U (en) | Kit for gastric cancer drug sensitivity test | |
| CN203144409U (en) | Kit for esophagus cancer drug sensitivity test | |
| CN203144405U (en) | Kit for lung cancer susceptibility detection | |
| CN203144404U (en) | Kit for cervical cancer susceptibility detection | |
| CN203144401U (en) | Kit for ovarian cancer drug sensitivity test | |
| CN203144406U (en) | Kit for liver cancer susceptibility detection | |
| CN203144411U (en) | Kit for prostatic cancer drug sensitivity test | |
| Zhao et al. | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma | |
| TW200940072A (en) | Pharmaceutical composition and extract of Poria for enhancing uptake of nutrients | |
| CN203144407U (en) | Kit for brain tumor drug sensitivity test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161018 Address after: 215007 No. 85 East Main Street, Jiangsu, Suzhou Patentee after: Suzhou innovac Medical Technology Consulting Co. Ltd. Address before: Xinghu street Suzhou Industrial Park in Jiangsu province 215125 No. 218 BioBAY A2 building room 330A Patentee before: Suzhou MacWell Biological Medicine Science and Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130821 Termination date: 20180326 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |